dabigatran etexilate 40 MG Oral Pellet
- RxCUI
- 2590631
- RxNorm name
- dabigatran etexilate 40 MG Oral Pellet
- Display name
- dabigatran etexilate 40 MG Oral Pellet
- Full name
- dabigatran etexilate 40 MG Oral Pellet
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:10
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pradaxa | DABIGATRAN ETEXILATE | Boehringer Ingelheim Pharmaceuticals, Inc. | 9ac0a64a-8666-45f7-9d4f-40fd894f7e6d | 2025-06-27 | Boxed warning, Warnings, Adverse reactions | 2590631 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 9ac0a64a-8666-45f7-9d4f-40fd894f7e6d | dabigatran etexilate 40 MG Oral Pellet | SCD | 7 | These highlights do not include all the information needed to use PRADAXA Oral Pellets safely and effectively. See full prescribing information for PRADAXA Oral Pellets. PRADAXA ® (dabigatran etexilate) oral pellets Initial U.S. Approval: 2010 | 20250627 |
| 9ac0a64a-8666-45f7-9d4f-40fd894f7e6d | dabigatran etexilate 40 MG (as dabigatran etexilate mesylate 46.12 MG) Oral Pellet | SY | 7 | These highlights do not include all the information needed to use PRADAXA Oral Pellets safely and effectively. See full prescribing information for PRADAXA Oral Pellets. PRADAXA ® (dabigatran etexilate) oral pellets Initial U.S. Approval: 2010 | 20250627 |
| 9ac0a64a-8666-45f7-9d4f-40fd894f7e6d | dabigatran etexilate 40 MG Oral Pellet | PSN | 7 | These highlights do not include all the information needed to use PRADAXA Oral Pellets safely and effectively. See full prescribing information for PRADAXA Oral Pellets. PRADAXA ® (dabigatran etexilate) oral pellets Initial U.S. Approval: 2010 | 20250627 |